Cargando…
Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures
BACKGROUND: An understanding of the experience of patients with progressive fibrosing interstitial lung disease (PF-ILD) is needed to select appropriate patient-reported outcome measures (PROMs) to evaluate treatment effect in clinical trials. METHODS: A systematic literature review was conducted to...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062300/ https://www.ncbi.nlm.nih.gov/pubmed/35509443 http://dx.doi.org/10.1183/23120541.00681-2021 |
_version_ | 1784698903773315072 |
---|---|
author | Wijsenbeek, Marlies Molina-Molina, Maria Chassany, Olivier Fox, John Galvin, Liam Geissler, Klaus Hammitt, Katherine M. Kreuter, Michael Moua, Teng O'Brien, Emily C. Slagle, Ashley F. Krasnow, Anna Reaney, Matthew Baldwin, Michael Male, Natalia Rohr, Klaus B. Swigris, Jeff Antoniou, Katerina |
author_facet | Wijsenbeek, Marlies Molina-Molina, Maria Chassany, Olivier Fox, John Galvin, Liam Geissler, Klaus Hammitt, Katherine M. Kreuter, Michael Moua, Teng O'Brien, Emily C. Slagle, Ashley F. Krasnow, Anna Reaney, Matthew Baldwin, Michael Male, Natalia Rohr, Klaus B. Swigris, Jeff Antoniou, Katerina |
author_sort | Wijsenbeek, Marlies |
collection | PubMed |
description | BACKGROUND: An understanding of the experience of patients with progressive fibrosing interstitial lung disease (PF-ILD) is needed to select appropriate patient-reported outcome measures (PROMs) to evaluate treatment effect in clinical trials. METHODS: A systematic literature review was conducted to develop a preliminary conceptual model of the symptoms experienced by patients with PF-ILD and the impacts the disease has on them. An online survey and consensus meetings were then conducted with 12–14 stakeholders (patients, clinicians, regulatory and payer advisors) to refine the conceptual model and critically appraise how key concepts should be measured by PROMs. PROMs assessed included Living with Idiopathic Pulmonary Fibrosis, Living with Pulmonary Fibrosis, the King's Brief Interstitial Lung Disease questionnaire, Cough and Sputum Assessment Questionnaire, Evaluating Respiratory Symptoms, Leicester Cough Questionnaire, Functional Assessment of Chronic Illness Therapy (Dyspnoea/Fatigue) and St George's Respiratory Questionnaire for Idiopathic Pulmonary Fibrosis. RESULTS: The literature review identified 36 signs/symptoms and 43 impacts directly or indirectly related to pulmonary aspects of PF-ILD. The most relevant symptoms identified by participants included shortness of breath on exertion, fatigue and cough; relevant impacts included effects on physical functioning, activities of daily living and emotional wellbeing. These are presented in a conceptual model. Consensus opinion was that existing PROMs need further modification and validation before use in clinical trials. CONCLUSIONS: The conceptual model improves understanding of the symptoms and impacts that living with PF-ILD has on patients’ wellbeing. It can help to inform the choice of PROMs in clinical trials and highlight aspects to assess in the clinical care of patients with PF-ILD. |
format | Online Article Text |
id | pubmed-9062300 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-90623002022-05-03 Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures Wijsenbeek, Marlies Molina-Molina, Maria Chassany, Olivier Fox, John Galvin, Liam Geissler, Klaus Hammitt, Katherine M. Kreuter, Michael Moua, Teng O'Brien, Emily C. Slagle, Ashley F. Krasnow, Anna Reaney, Matthew Baldwin, Michael Male, Natalia Rohr, Klaus B. Swigris, Jeff Antoniou, Katerina ERJ Open Res Original Research Articles BACKGROUND: An understanding of the experience of patients with progressive fibrosing interstitial lung disease (PF-ILD) is needed to select appropriate patient-reported outcome measures (PROMs) to evaluate treatment effect in clinical trials. METHODS: A systematic literature review was conducted to develop a preliminary conceptual model of the symptoms experienced by patients with PF-ILD and the impacts the disease has on them. An online survey and consensus meetings were then conducted with 12–14 stakeholders (patients, clinicians, regulatory and payer advisors) to refine the conceptual model and critically appraise how key concepts should be measured by PROMs. PROMs assessed included Living with Idiopathic Pulmonary Fibrosis, Living with Pulmonary Fibrosis, the King's Brief Interstitial Lung Disease questionnaire, Cough and Sputum Assessment Questionnaire, Evaluating Respiratory Symptoms, Leicester Cough Questionnaire, Functional Assessment of Chronic Illness Therapy (Dyspnoea/Fatigue) and St George's Respiratory Questionnaire for Idiopathic Pulmonary Fibrosis. RESULTS: The literature review identified 36 signs/symptoms and 43 impacts directly or indirectly related to pulmonary aspects of PF-ILD. The most relevant symptoms identified by participants included shortness of breath on exertion, fatigue and cough; relevant impacts included effects on physical functioning, activities of daily living and emotional wellbeing. These are presented in a conceptual model. Consensus opinion was that existing PROMs need further modification and validation before use in clinical trials. CONCLUSIONS: The conceptual model improves understanding of the symptoms and impacts that living with PF-ILD has on patients’ wellbeing. It can help to inform the choice of PROMs in clinical trials and highlight aspects to assess in the clinical care of patients with PF-ILD. European Respiratory Society 2022-05-03 /pmc/articles/PMC9062300/ /pubmed/35509443 http://dx.doi.org/10.1183/23120541.00681-2021 Text en Copyright ©The authors 2022 https://creativecommons.org/licenses/by/4.0/This article is open access and distributed under the terms of the Creative Commons Attribution Licence 4.0. |
spellingShingle | Original Research Articles Wijsenbeek, Marlies Molina-Molina, Maria Chassany, Olivier Fox, John Galvin, Liam Geissler, Klaus Hammitt, Katherine M. Kreuter, Michael Moua, Teng O'Brien, Emily C. Slagle, Ashley F. Krasnow, Anna Reaney, Matthew Baldwin, Michael Male, Natalia Rohr, Klaus B. Swigris, Jeff Antoniou, Katerina Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures |
title | Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures |
title_full | Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures |
title_fullStr | Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures |
title_full_unstemmed | Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures |
title_short | Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures |
title_sort | developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062300/ https://www.ncbi.nlm.nih.gov/pubmed/35509443 http://dx.doi.org/10.1183/23120541.00681-2021 |
work_keys_str_mv | AT wijsenbeekmarlies developingaconceptualmodelofsymptomsandimpactsinprogressivefibrosinginterstitiallungdiseasetoevaluatepatientreportedoutcomemeasures AT molinamolinamaria developingaconceptualmodelofsymptomsandimpactsinprogressivefibrosinginterstitiallungdiseasetoevaluatepatientreportedoutcomemeasures AT chassanyolivier developingaconceptualmodelofsymptomsandimpactsinprogressivefibrosinginterstitiallungdiseasetoevaluatepatientreportedoutcomemeasures AT foxjohn developingaconceptualmodelofsymptomsandimpactsinprogressivefibrosinginterstitiallungdiseasetoevaluatepatientreportedoutcomemeasures AT galvinliam developingaconceptualmodelofsymptomsandimpactsinprogressivefibrosinginterstitiallungdiseasetoevaluatepatientreportedoutcomemeasures AT geisslerklaus developingaconceptualmodelofsymptomsandimpactsinprogressivefibrosinginterstitiallungdiseasetoevaluatepatientreportedoutcomemeasures AT hammittkatherinem developingaconceptualmodelofsymptomsandimpactsinprogressivefibrosinginterstitiallungdiseasetoevaluatepatientreportedoutcomemeasures AT kreutermichael developingaconceptualmodelofsymptomsandimpactsinprogressivefibrosinginterstitiallungdiseasetoevaluatepatientreportedoutcomemeasures AT mouateng developingaconceptualmodelofsymptomsandimpactsinprogressivefibrosinginterstitiallungdiseasetoevaluatepatientreportedoutcomemeasures AT obrienemilyc developingaconceptualmodelofsymptomsandimpactsinprogressivefibrosinginterstitiallungdiseasetoevaluatepatientreportedoutcomemeasures AT slagleashleyf developingaconceptualmodelofsymptomsandimpactsinprogressivefibrosinginterstitiallungdiseasetoevaluatepatientreportedoutcomemeasures AT krasnowanna developingaconceptualmodelofsymptomsandimpactsinprogressivefibrosinginterstitiallungdiseasetoevaluatepatientreportedoutcomemeasures AT reaneymatthew developingaconceptualmodelofsymptomsandimpactsinprogressivefibrosinginterstitiallungdiseasetoevaluatepatientreportedoutcomemeasures AT baldwinmichael developingaconceptualmodelofsymptomsandimpactsinprogressivefibrosinginterstitiallungdiseasetoevaluatepatientreportedoutcomemeasures AT malenatalia developingaconceptualmodelofsymptomsandimpactsinprogressivefibrosinginterstitiallungdiseasetoevaluatepatientreportedoutcomemeasures AT rohrklausb developingaconceptualmodelofsymptomsandimpactsinprogressivefibrosinginterstitiallungdiseasetoevaluatepatientreportedoutcomemeasures AT swigrisjeff developingaconceptualmodelofsymptomsandimpactsinprogressivefibrosinginterstitiallungdiseasetoevaluatepatientreportedoutcomemeasures AT antonioukaterina developingaconceptualmodelofsymptomsandimpactsinprogressivefibrosinginterstitiallungdiseasetoevaluatepatientreportedoutcomemeasures |